在头部和部癌症的联合计量化学免疫疗法 (CMCI) - - 一个发展中国家的经验
Irappa Madabhavi1,2,3, Malay Sarkar4, Vineet Kumar5
1Department of Medical and Pediatric Oncology and Hematology, J N Medical College and KLE Academy of Higher Education and Research, Belagavi, India.
Indian journal of surgical oncology
|May 14, 2024
概括
这项研究表明,将尼沃卢马布 (免疫疗法) 与capecitabine (化疗) 结合起来,对于晚期头癌提供了显著的临床益处. 这种组合治疗证明了66%的临床益处率和改善了重度预治疗患者的生存结果.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 化疗 化疗是一种化学疗法.
背景情况:
- 头部和部状细胞癌 (HNSCC) 表现出对全身治疗的固有抵抗力.
- 在标准化疗进展后,对于HNSCC存在有限的治疗选择.
- 免疫疗法为改善高级HNSCC的结果提供了一个有希望的途径.
研究的目的:
- 评估在患有晚期,复发或转移性HNSCC的患者中将尼沃卢马布与低剂量capecitabine结合使用的疗效和安全性.
- 评估这种联合治疗的临床益处率 (CBR),总生存率 (OS) 和无进展生存率 (PFS).
主要方法:
- 一项前性,观察性,非随机化,开放标签研究,涉及12名患有高级HNSCC的患者.
- 患者接受了尼沃卢马布 (3 mg/kg每两周一次) 加上低剂量的capecitabine (每天两次500 mg).
- 记录了临床,血液学和分期特征,并计算了CBR.
主要成果:
- 观察到66% (8/12名患者) 的临床益处率 (CBR).
- 六个月总生存率 (OS) 为83.3%,六个月无进展生存率 (PFS) 为66.6%.
- 组合疗法一般耐受良好,没有3/4级免疫相关不良事件 (IRAE).
结论:
- 尼沃卢马布与计量学性capecitabine结合,耐受性良好,并且在广泛预先治疗的HNSCC患者中表现出抗瘤活性.
- 该组合实现了66%的CBR,83.3%的6个月的OS和66.6%的6个月的PFS.
- 对尼沃卢马布和计量化学疗法组合的进一步研究是有必要的.
相关概念视频
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:27Tumor Immunotherapy
518
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
518
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K